DiaMedica Total Assets from 2010 to 2026

DMAC Stock  USD 8.17  0.23  2.74%   
DiaMedica Therapeutics' Total Assets are increasing over the years with slightly volatile fluctuation. Overall, Total Assets are expected to go to about 56 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals
 
Total Assets  
First Reported
2005-12-31
Previous Quarter
31.5 M
Current Value
57 M
Quarterly Volatility
18.3 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check DiaMedica Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DiaMedica Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.3 K, Interest Expense of 426.2 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 49.24, Dividend Yield of 0.0 or PTB Ratio of 5.09. DiaMedica financial statements analysis is a perfect complement when working with DiaMedica Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with DiaMedica Stock
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
Analyzing DiaMedica Therapeutics's Total Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Assets has evolved provides context for assessing DiaMedica Therapeutics's current valuation and future prospects.

Latest DiaMedica Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of DiaMedica Therapeutics over the last few years. Total assets refers to the total amount of DiaMedica Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in DiaMedica Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. DiaMedica Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DiaMedica Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 46.34 M10 Years Trend
Slightly volatile
   Total Assets   
       Timeline  

DiaMedica Total Assets Regression Statistics

Arithmetic Mean21,333,633
Geometric Mean6,888,266
Coefficient Of Variation103.84
Mean Deviation19,819,871
Median9,053,000
Standard Deviation22,152,908
Sample Variance490.8T
Range55.7M
R-Value0.90
Mean Square Error95.6T
R-Squared0.82
Slope3,966,035
Total Sum of Squares7852T

DiaMedica Total Assets History

202656 M
202553.3 M
202446.3 M
202354.2 M
202234.4 M
202145.6 M
202028.1 M

Other Fundumenentals of DiaMedica Therapeutics

DiaMedica Therapeutics Total Assets component correlations

About DiaMedica Therapeutics Financial Statements

DiaMedica Therapeutics stakeholders use historical fundamental indicators, such as DiaMedica Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Although DiaMedica Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DiaMedica Therapeutics' assets and liabilities are reflected in the revenues and expenses on DiaMedica Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DiaMedica Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Assets53.3 M56 M
Intangibles To Total Assets 0.11  0.10 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Will Biotechnology sector continue expanding? Could DiaMedica diversify its offerings? Factors like these will boost the valuation of DiaMedica Therapeutics. Projected growth potential of DiaMedica fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DiaMedica Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.71)
Return On Assets
(0.38)
Return On Equity
(0.64)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DiaMedica Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DiaMedica Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DiaMedica Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.